Modulation of matrix metalloproteinase and cytokine production by licorice isolates licoricidin and licorisoflavan A: Potential therapeutic approach for periodontitis

Journal of Periodontology

Volumn 82, Issue 1, 2011, Pages 122-128

  La, Vu Dang ^a   Tanabe, Shin Ichi ^a   Bergeron, Chantal ^b   Gafner, Stefan ^b   Grenier, Daniel ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b Tom's of Maine   (United States)

Author keywords

Anti inflammatory agent; Cytokine; Inflammation; Innate immunity; Matrix metalloproteinase; Periodontitis

Indexed keywords

AUTACOID; BENZOPYRAN DERIVATIVE; CYTOKINE; ENZYME INHIBITOR; FLAVONOID; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; LICORICIDIN; LICORISOFLAVAN A; LIPOPOLYSACCHARIDE; MATRILYSIN; MATRIX METALLOPROTEINASE; MMP7 PROTEIN, HUMAN; MMP8 PROTEIN, HUMAN; NEUTROPHIL COLLAGENASE; PLANT EXTRACT; RANTES; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GLYCYRRHIZA; HUMAN; IMMUNOLOGY; MACROPHAGE; TUMOR CELL LINE;

ACTINOBACILLUS ACTINOMYCETEMCOMITANS; BENZOPYRANS; CELL LINE, TUMOR; CHEMOKINE CCL5; CYTOKINES; ENZYME INHIBITORS; FLAVONOIDS; GLYCYRRHIZA; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MACROPHAGES; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PLANT EXTRACTS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA;

EID: 79251617999     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2010.100342     Document Type: Article

References (42)

1. Okada H, Murakami S. Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med 1998;9:248-266.
2. Bascones A, Noronha S, Gómez M, Mota P, Gó nzalez Moles MA, Villarroel Dorrego M. Tissue destruction in periodontitis: Bacteria or cytokines fault? Quintessence Int 2005;36:299-306.
3. Cox SW, Eley BM, Kiili M, Asikainen A, Tervahartiala T, Sorsa T. Collagen degradation by interleukin-1betastimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases. Oral Dis 2006;12:34-40.
4. Irwin CR, Myrillas TT, Traynor P, Leadbetter N, Cawston TE. The role of soluble interleukin (IL)-6 receptor in mediating the effects of IL-6 on matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 expression by gingival fibroblasts. J Periodontol 2002;73:741-747.
5. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. J Periodontal Res 1993;28:500-510.
6. Sorsa T, Tjäderhane L, Konttinen YT, et al. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006;38:306-321.
7. Sorsa T, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 2004;10:311-318.
8. Davis EA, Morris DJ. Medicinal uses of licorice through the millennia: The good and plenty of it. Mol Cell Endocrinol 1991;78:1-6.
9. Fiore C, Eisenhut M, Ragazzi E, Zanchin G, Armanini D. A history of the therapeutic use of liquorice in Europe. J Ethnopharmacol 2005;99:317-324.
10. Isbrucker RA, Burdock GA. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol 2006;46:167-192.
11. Martin MD, Sherman J, van der Ven P, Burgess J. A controlled trial of a dissolving oral patch concerning glycyrrhiza (licorice) herbal extract for the treatment of aphthous ulcers. Gen Dent 2008;56:206-210; quiz 211-212, 224.
12. Steinberg D, Sgan-Cohen HD, Stabholz A, Pizanty S, Segal R, Sela MN. The anticariogenic activity of glycyrrhizin: Preliminary clinical trials. Isr J Dent Sci 1989;2:153-157.
13. Segal R, Pisanty S, Wormser R, Azaz E, Sela MN. Anticariogenic activity of licorice and glycyrrhizine I: Inhibition of in vitro plaque formation by Streptococcus mutans. J Pharm Sci 1985;74:79-81.
14. He J, Chen L, Heber D, Shi W, Lu QY. Antibacterial compounds from Glycyrrhiza uralensis. J Nat Prod 2006;69:121-124.
15. Bodet C, La VD, Gafner S, Bergeron C, Grenier D. A licorice extract reduces lipopolysaccharide-induced proinflammatory cytokine secretion by macrophages and whole blood. J Periodontol 2008;79:1752-1761.
16. Darveau RP, Hancock RE. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol 1983;155:831-838.
17. Rovera G, Santoli D, Damsky C. Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA 1979;76:2779-2783.
18. Zappa U, Reinking-Zappa M, Graf H, Espeland M. Cell populations and episodic periodontal attachment loss in humans. J Clin Periodontol 1991;18:508-515.
19. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKLindependent mechanism. Bone 2003;32:1-7.
20. Kusano K, Miyaura C, Inada M, et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: Association of MMP induction with bone resorption. Endocrinology 1998;139:1338-1345.
21. Vidal F, Figueredo CM, Cordovil I, Fischer RG. Periodontal therapy reduces plasma levels of interleukin-6, C-reactive protein, and fibrinogen in patients with severe periodontitis and refractory arterial hypertension. J Periodontol 2009;80:786-791.
22. Marcaccini AM, Meschiari CA, Sorgi CA, et al. Circulating interleukin-6 and high-sensitivity C-reactive protein decrease after periodontal therapy in otherwise healthy subjects. J Periodontol 2009;80:594-602.
23. Takahashi K, Takashiba S, Nagai A, et al. Assessment of interleukin-6 in the pathogenesis of periodontal disease. J Periodontol 1994;65:147-153.
24. Gamonal J, Acevedo A, Bascones A, Jorge O, Silva A. Characterization of cellular infiltrate, detection of chemokine receptor CCR5 and interleukin-8 and RANTES chemokines in adult periodontitis. J Periodontal Res 2001;36:194-203.
25. Gamonal J, Bascones A, Jorge O, Silva A. Chemokine RANTES in gingival crevicular fluid of adult patients with periodontitis. J Clin Periodontol 2000;27:675-681.
26. Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol 2004;75:37-43.
27. Bodet C, Chandad F, Grenier D. Anti-inflammatory activity of a high-molecular-weight cranberry fraction on macrophages stimulated by lipopolysaccharides from periodontopathogens. J Dent Res 2006;85:235-239.
28. Soell M, Elkaim R, Tenenbaum H. Cathepsin C, matrix metalloproteinases, and their tissue inhibitors in gingiva and gingival crevicular fluid from periodontitisaffected patients. J Dent Res 2002;81:174-178.
29. Emingil G, Tervahartiala T, Mantyla P, Määttä M, Sorsa T, Atilla G. Gingival crevicular fluid matrix metalloproteinase (MMP)-7, extracellular MMP inducer, and tissue inhibitor of MMP-1 levels in periodontal disease. J Periodontol 2006;77:2040-2050.
30. Kivelä-Rajamäki M, Maisi P, Srinivas R, et al. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid. J Periodontal Res 2003;38:583-590.
31. Wilson CL, Matrisian LM. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996;28:123-136.
32. Herr AE, Hatch AV, Throckmorton DJ, et al. Microfluidic immunoassays as rapid saliva-based clinical diagnostics. Proc Natl Acad Sci USA 2007;104:5268-5273.
33. Rai B, Kharb S, Jain R, Anand SC. Biomarkers of periodontitis in oral fluids. J Oral Sci 2008;50:53-56.
34. Marcaccini AM, Meschiari CA, Zuardi LR, et al. Gingival crevicular fluid levels of MMP-8, MMP-9, TIMP-2, and MPO decrease after periodontal therapy. J Clin Periodontol 2010;37:180-190.
35. Teng YT, Sodek J, McCulloch CA. Gingival crevicular fluid gelatinase and its relationship to periodontal disease in human subjects. J Periodontal Res 1992;27:544-552.
36. Smith PC, Muñoz VC, Collados L, Oyarzún AD. In situ detection of matrix metalloproteinase-9 (MMP-9) in gingival epithelium in human periodontal disease. J Periodontal Res 2004;39:87-92.
37. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008;40:1362-1378.
38. Nichols TC, Fischer TH, Deliargyris EN, Baldwin AS Jr. Role of nuclear factor-kappa B (NF-kappa B) in inflammation, periodontitis, and atherogenesis. Ann Periodontol 2001;6:20-29.
39. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008;8:837-848.
40. Furusawa J, Funakoshi-Tago M, Mashino T, et al. Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway. Int Immunopharmacol 2009;9:499-507.
41. Furusawa J, Funakoshi-Tago M, Tago K, et al. Licochalcone A significantly suppresses LPS signaling pathway through the inhibition of NF-kappaB p65 phosphorylation at serine 276. Cell Signal 2009;21: 778-785.
42. Lee HM, Ciancio SG, Tüter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004;75:453-463.